Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Clinical Research in Cardiology
Erschienen in: Clinical Research in Cardiology 3/2024

14.12.2023 | Original Paper

Multi-parametric non-contrast cardiac magnetic resonance for the differentiation between cardiac amyloidosis and hypertrophic cardiomyopathy

verfasst von: Henning Steen, Moritz Montenbruck, Alexandros Kallifatidis, Florian André, Norbert Frey, Sebastian Kelle, Grigorios Korosoglou

Erschienen in: Clinical Research in Cardiology | Ausgabe 3/2024

Einloggen, um Zugang zu erhalten

Abstract

Aim

To evaluate the ability of fast strain-encoded (SENC) cardiac magnetic resonance (CMR) derived myocardial strain and native T1 mapping to discriminate between hypertrophic cardiomyopathy (HCM) and cardiac amyloidosis.

Methods

Ninety nine patients (57 with hypertrophic cardiomyopathy and 42 with cardiac amyloidosis) were systematically analysed. LV-ejection fraction, LV-mass index, septal wall thickness and native T1 mapping values were assessed. In addition, global circumferential and longitudinal strain and segmental circumferential and longitudinal strain in basal, mid-ventricular, and apical segments were calculated. A ratio was built by dividing native T1 values by basal segmental strain (T1-to-basal segmental strain ratio).

Results

Myocardial strain was equally distributed in apical and basal segments in HCM patients, whereas an apical sparing with less impaired apical strain was noticed in cardiac amyloidosis (apical-to-basal-ratio of 1.01 ± 0.23 versus 1.20 ± 0.28, p < 0.001). T1 values were significantly higher in amyloidosis compared to HCM patients (1170.7 ± 66.4 ms versus 1078.3 ± 57.4ms, p < 0.001). The T1-to-basal segmental strain ratio exhibited high accuracy for the differentiation between the two clinical entities (Sensitivity = 85%, Specificity = 77%, AUC = 0.90, 95% CI = 0.81–0.95, p < 0.001). Multivariable analysis showed that age and the T1-to-basal-strain-ratio were the most robust factors for the differentiation between HCM and cardiac amyloidosis.

Conclusion

The T1-to-basal-segmental strain ratio, combining information from segmental circumferential and longitudinal strain and native T1 mapping aids the differentiation between HCM and cardiac amyloidosis with high accuracy and within a fast CMR protocol, obviating the need for contrast agent administration.

Graphical abstract

Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
McKenna WJ, Maron BJ, Thiene G (2017) Classification, Epidemiology, and Global Burden of Cardiomyopathies. Circ Res 121(7):722–730PubMedCrossRef
2.
Korosoglou G, Giusca S, Andre F et al (2021) Diagnostic work-up of cardiac amyloidosis using cardiovascular imaging: current standards and practical algorithms. Vasc Health Risk Manag 17:661–673PubMedPubMedCentralCrossRef
3.
Glenner GG, Terry W, Harada M, Isersky C, Page D (1971) Amyloid fibril proteins: proof of homology with immunoglobulin light chains by sequence analyses. Science 172(3988):1150–1151ADSPubMedCrossRef
4.
Maurizi N, Rella V, Fumagalli C et al (2020) Prevalence of cardiac amyloidosis among adult patients referred to tertiary centres with an initial diagnosis of hypertrophic cardiomyopathy. Int J Cardiol 300:191–195PubMedCrossRef
5.
Ney S, Ihle P, Ruhnke T et al (2023) Epidemiology of cardiac amyloidosis in Germany: a retrospective analysis from 2009 to 2018. Clin Res Cardiol 112(3):401–408PubMedCrossRef
6.
Chamling B, Bietenbeck M, Korthals D et al (2023) Therapeutic value of tafamidis in patients with wild-type transthyretin amyloidosis (ATTRwt) with cardiomyopathy based on cardiovascular magnetic resonance (CMR) imaging. Clin Res Cardiol 112(3):353–362PubMedCrossRef
7.
Puntmann VO, Peker E, Chandrashekhar Y, Nagel E (2016) T1 Mapping in characterizing myocardial disease: a comprehensive review. Circ Res 119(2):277–299PubMedCrossRef
8.
Korosoglou G, Giusca S, Gitsioudis G, Erbel C, Katus HA (2014) Cardiac magnetic resonance and computed tomography angiography for clinical imaging of stable coronary artery disease. Diagnostic classification and risk stratification. Front Physiol 5: 291.
9.
Giusca S, Steen H, Montenbruck M et al (2021) Multi-parametric assessment of left ventricular hypertrophy using late gadolinium enhancement, T1 mapping and strain-encoded cardiovascular magnetic resonance. J Cardiovasc Magn Reson 23(1):92PubMedPubMedCentralCrossRef
10.
Tang W, McDonald SP, Hawley CM et al (2013) End-stage renal failure due to amyloidosis: outcomes in 490 ANZDATA registry cases. Nephrol Dial Transplant 28(2):455–461PubMedCrossRef
11.
Phelan D, Collier P, Thavendiranathan P et al (2012) Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis. Heart 98(19):1442–1448PubMedCrossRef
12.
Liu D, Hu K, Niemann M et al (2013) Effect of combined systolic and diastolic functional parameter assessment for differentiation of cardiac amyloidosis from other causes of concentric left ventricular hypertrophy. Circ Cardiovasc Imaging 6(6):1066–1072PubMedCrossRef
13.
Maron BJ, Ommen SR, Semsarian C, Spirito P, Olivotto I, Maron MS (2014) Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine. J Am Coll Cardiol 64(1):83–99PubMedCrossRef
14.
Gertz MA, Comenzo R, Falk RH et al (2005) Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18–22 April 2004. Am J Hematol 79(4):319–328PubMedCrossRef
15.
Prakken NH, Velthuis BK, Teske AJ, Mosterd A, Mali WP, Cramer MJ (2010) Cardiac MRI reference values for athletes and nonathletes corrected for body surface area, training hours/week and sex. Eur J Cardiovasc Prev Rehabil 17(2):198–203PubMedCrossRef
16.
Yilmaz A, Bauersachs J, Bengel F et al (2021) Diagnosis and treatment of cardiac amyloidosis: position statement of the German Cardiac Society (DGK). Clin Res Cardiol 110(4):479–506PubMedPubMedCentralCrossRef
17.
Messroghli DR, Moon JC, Ferreira VM et al (2017) Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: a consensus statement by the society for cardiovascular magnetic resonance (SCMR) endorsed by the European association for cardiovascular imaging (EACVI). J Cardiovasc Magn Reson 19(1):75PubMedPubMedCentralCrossRef
18.
Cardim N, Galderisi M, Edvardsen T et al (2015) Role of multimodality cardiac imaging in the management of patients with hypertrophic cardiomyopathy: an expert consensus of the European Association of Cardiovascular Imaging Endorsed by the Saudi Heart Association. Eur Heart J Cardiovasc Imaging 16(3):280PubMedCrossRef
19.
Giusca S, Korosoglou G, Zieschang V et al (2018) Reproducibility study on myocardial strain assessment using fast-SENC cardiac magnetic resonance imaging. Sci Rep 8(1):14100ADSPubMedPubMedCentralCrossRef
20.
Korosoglou G, Giusca S, Hofmann NP et al (2019) Strain-encoded magnetic resonance: a method for the assessment of myocardial deformation. ESC Heart Fail 6(4):584–602PubMedPubMedCentralCrossRef
21.
Steen H, Giusca S, Montenbruck M et al (2021) Left and right ventricular strain using fast strain-encoded cardiovascular magnetic resonance for the diagnostic classification of patients with chronic non-ischemic heart failure due to dilated, hypertrophic cardiomyopathy or cardiac amyloidosis. J Cardiovasc Magn Reson 23(1):45PubMedPubMedCentralCrossRef
22.
Korosoglou G, Giusca S, Montenbruck M et al (2021) Fast Strain-Encoded Cardiac Magnetic Resonance for Diagnostic Classification and Risk Stratification of Heart Failure Patients. JACC Cardiovasc Imaging 14(6):1177–1188PubMedCrossRef
23.
Cerqueira MD, Weissman NJ, Dilsizian V, et al. (2002) Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the cardiac imaging committee of the council on clinical cardiology of the american heart association. Circulation 105(4): 539–42.
24.
Williams LK, Forero JF, Popovic ZB et al (2017) Patterns of CMR measured longitudinal strain and its association with late gadolinium enhancement in patients with cardiac amyloidosis and its mimics. J Cardiovasc Magn Reson 19(1):61PubMedPubMedCentralCrossRef
25.
Bravo PE, Fujikura K, Kijewski MF et al (2019) Relative apical sparing of myocardial longitudinal strain is explained by regional differences in total amyloid mass rather than the proportion of amyloid deposits. JACC Cardiovasc Imaging 12(7 Pt 1):1165–1173PubMedCrossRef
26.
Dass S, Suttie JJ, Piechnik SK et al (2012) Myocardial tissue characterization using magnetic resonance noncontrast t1 mapping in hypertrophic and dilated cardiomyopathy. Circ Cardiovasc Imaging 5(6):726–733PubMedCrossRef
27.
Hosch W, Bock M, Libicher M et al (2007) MR-relaxometry of myocardial tissue: significant elevation of T1 and T2 relaxation times in cardiac amyloidosis. Invest Radiol 42(9):636–642PubMedCrossRef
28.
Fontana M, Banypersad SM, Treibel TA et al (2014) Native T1 mapping in transthyretin amyloidosis. JACC Cardiovasc Imaging 7(2):157–165PubMedCrossRef
29.
Lavall D, Vosshage NH, Gessner R et al (2023) Native T1 mapping for the diagnosis of cardiac amyloidosis in patients with left ventricular hypertrophy. Clin Res Cardiol 112(3):334–342PubMedCrossRef
30.
Karamitsos TD, Piechnik SK, Banypersad SM et al (2013) Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imaging 6(4):488–497PubMedCrossRef
31.
Wang TKM, Brizneda MV, Kwon DH et al (2021) Reference ranges, diagnostic and prognostic utility of native T1 mapping and extracellular volume for cardiac amyloidosis: a meta-analysis. J Magn Reson Imaging 53(5):1458–1468PubMedCrossRef
32.
Pan JA, Kerwin MJ, Salerno M (2020) Native T1 mapping, extracellular volume mapping, and late gadolinium enhancement in cardiac amyloidosis: a meta-analysis. JACC Cardiovasc Imaging 13(6):1299–1310PubMedPubMedCentralCrossRef
33.
Vo HQ, Marwick TH, Negishi K (2020) Pooled summary of native T1 value and extracellular volume with MOLLI variant sequences in normal subjects and patients with cardiovascular disease. Int J Cardiovasc Imaging 36(2):325–336PubMedCrossRef
34.
35.
de Boer RA, Heymans S, Backs J, et al. (2022) Targeted therapies in genetic dilated and hypertrophic cardiomyopathies: from molecular mechanisms to therapeutic targets. A position paper from the Heart Failure Association (HFA) and the Working Group on Myocardial Function of the European Society of Cardiology (ESC). Eur J Heart Fail 24(3): 406–20.
36.
Maurer MS, Schwartz JH, Gundapaneni B et al (2018) Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 379(11):1007–1016PubMedCrossRef
37.
Antonopoulos AS, Panagiotopoulos I, Kouroutzoglou A et al (2022) Prevalence and clinical outcomes of transthyretin amyloidosis: a systematic review and meta-analysis. Eur J Heart Fail 24(9):1677–1696PubMedCrossRef
38.
Bianchi G, Zhang Y, Comenzo RL (2021) AL amyloidosis: current chemotherapy and immune therapy treatment strategies: JACC: CardioOncology state-of-the-art review. JACC CardioOncol 3(4):467–487PubMedPubMedCentralCrossRef
39.
Martens P, Hanna M, Valent J, Estep JD, Tang WHW (2023) Supra-normal left ventricular ejection fraction in cardiac amyloidosis. Clin Res Cardiol 112(3):441–443PubMedCrossRef
40.
Wheeler MT, Olivotto I, Elliott PM, et al. Effects of Mavacamten on Measures of Cardiopulmonary Exercise Testing Beyond Peak Oxygen Consumption: A Secondary Analysis of the EXPLORER-HCM Randomized Trial. JAMA Cardiol 2023.
41.
Korthals D, Chatzantonis G, Bietenbeck M, Meier C, Stalling P, Yilmaz A (2021) CMR-based T1-mapping offers superior diagnostic value compared to longitudinal strain-based assessment of relative apical sparing in cardiac amyloidosis. Sci Rep 11(1):15521PubMedPubMedCentralCrossRef
42.
Korosoglou G, Giusca S (2020) Strain for stress testing: Is it a featuring or supporting role in cardiac magnetic resonance? JACC Cardiovasc Imaging 13(1 Pt 1):66–68PubMedCrossRef
43.
Yue X, Yang L, Wang R et al (2022) The diagnostic value of multiparameter cardiovascular magnetic resonance for early detection of light-chain amyloidosis from hypertrophic cardiomyopathy patients. Front Cardiovasc Med 9:1017097PubMedPubMedCentralCrossRef
44.
Korosoglou G, Ochs M (2023) Spotlight on myocardial deformation in hypertrophic cardiomyopathy: Putting the puzzle together? JACC Cardiovasc Imaging 16(4):492–494PubMedCrossRef
45.
Amr A, Koelemen J, Reich C, et al. (2023) Improving sudden cardiac death risk stratification in hypertrophic cardiomyopathy using established clinical variables and genetic information. Clin Res Cardiol.
46.
Cheng S, Larson MG, McCabe EL et al (2013) Age- and sex-based reference limits and clinical correlates of myocardial strain and synchrony: the Framingham Heart Study. Circ Cardiovasc Imaging 6(5):692–699PubMedCrossRef
Metadaten
Titel
Multi-parametric non-contrast cardiac magnetic resonance for the differentiation between cardiac amyloidosis and hypertrophic cardiomyopathy
verfasst von
Henning Steen
Moritz Montenbruck
Alexandros Kallifatidis
Florian André
Norbert Frey
Sebastian Kelle
Grigorios Korosoglou
Publikationsdatum
14.12.2023
Verlag
Springer Berlin Heidelberg
Erschienen in
Clinical Research in Cardiology / Ausgabe 3/2024
Print ISSN: 1861-0684
Elektronische ISSN: 1861-0692
DOI
https://doi.org/10.1007/s00392-023-02348-4

Weitere Artikel der Ausgabe 3/2024

Clinical Research in Cardiology 3/2024 Zur Ausgabe

Review

Validating real-time three-dimensional echocardiography against cardiac magnetic resonance, for the determination of ventricular mass, volume and ejection fraction: a meta-analysis

Original Paper

Lung ultrasound and diuretic therapy in chronic heart failure: a randomised trial

Original Paper

Impact of coronary CT angiography in selection of treatment modalities and subsequent cardiovascular events in Thai patients with stable CAD

Original Paper

Real-time cardiovascular magnetic resonance imaging for non-invasive characterisation of heart failure with preserved ejection fraction: final outcomes of the HFpEF stress trial

Original Paper

Echocardiographic predictors of outcome in severe aortic stenosis patients with preserved or reduced ejection fraction

Original Paper

Safety of dobutamine or adenosine stress cardiac magnetic resonance imaging in patients with left ventricular thrombus

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen